Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 97
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Immunity ; 54(1): 132-150.e9, 2021 01 12.
Article in English | MEDLINE | ID: mdl-33271119

ABSTRACT

HLA class I (HLA-I) glycoproteins drive immune responses by presenting antigens to cognate CD8+ T cells. This process is often hijacked by tumors and pathogens for immune evasion. Because options for restoring HLA-I antigen presentation are limited, we aimed to identify druggable HLA-I pathway targets. Using iterative genome-wide screens, we uncovered that the cell surface glycosphingolipid (GSL) repertoire determines effective HLA-I antigen presentation. We show that absence of the protease SPPL3 augmented B3GNT5 enzyme activity, resulting in upregulation of surface neolacto-series GSLs. These GSLs sterically impeded antibody and receptor interactions with HLA-I and diminished CD8+ T cell activation. Furthermore, a disturbed SPPL3-B3GNT5 pathway in glioma correlated with decreased patient survival. We show that the immunomodulatory effect could be reversed through GSL synthesis inhibition using clinically approved drugs. Overall, our study identifies a GSL signature that inhibits immune recognition and represents a potential therapeutic target in cancer, infection, and autoimmunity.


Subject(s)
Aspartic Acid Endopeptidases/metabolism , CD8-Positive T-Lymphocytes/immunology , Glioma/immunology , Glycosphingolipids/metabolism , Glycosyltransferases/metabolism , HLA Antigens/metabolism , Histocompatibility Antigens Class I/metabolism , Immunotherapy/methods , Antigen Presentation , Aspartic Acid Endopeptidases/genetics , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Gene Knockdown Techniques , Glioma/mortality , Glycosphingolipids/immunology , HLA Antigens/immunology , Histocompatibility Antigens Class I/immunology , Humans , Lymphocyte Activation , Signal Transduction , Survival Analysis , Tumor Escape
3.
Nat Immunol ; 12(1): 45-53, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21151101

ABSTRACT

Cytotoxic T lymphocytes (CTLs) recognize peptides presented by HLA class I molecules on the cell surface. The C terminus of these CTL epitopes is considered to be produced by the proteasome. Here we demonstrate that the cytosolic endopeptidases nardilysin and thimet oligopeptidase (TOP) complemented proteasome activity. Nardilysin and TOP were required, either together or alone, for the generation of a tumor-specific CTL epitope from PRAME, an immunodominant CTL epitope from Epstein-Barr virus protein EBNA3C, and a clinically important epitope from the melanoma protein MART-1. TOP functioned as C-terminal trimming peptidase in antigen processing, and nardilysin contributed to both the C-terminal and N-terminal generation of CTL epitopes. By broadening the antigenic peptide repertoire, nardilysin and TOP strengthen the immune defense against intracellular pathogens and cancer.


Subject(s)
Antigens, Neoplasm/metabolism , Epitopes, T-Lymphocyte/metabolism , Metalloendopeptidases/metabolism , T-Lymphocytes, Cytotoxic/metabolism , Antigen Presentation/genetics , Antigens, Neoplasm/chemistry , Antigens, Neoplasm/immunology , Cytotoxicity, Immunologic/genetics , Epitopes, T-Lymphocyte/chemistry , Epitopes, T-Lymphocyte/immunology , HLA-A3 Antigen/metabolism , Humans , K562 Cells , Metalloendopeptidases/genetics , Metalloendopeptidases/immunology , Peptide Fragments/chemistry , Peptide Fragments/immunology , Peptide Fragments/metabolism , Proteasome Endopeptidase Complex/metabolism , Protein Binding , RNA, Small Interfering/genetics , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/pathology , Transgenes/genetics
4.
J Immunol ; 206(8): 1957-1965, 2021 04 15.
Article in English | MEDLINE | ID: mdl-33692147

ABSTRACT

MHC class I molecules play an important role in adaptive immune responses against intracellular pathogens. These molecules are highly polymorphic, and many allotypes have been characterized. In a transplantation setting, a mismatch between MHC allotypes may initiate an alloimmune response. Rhesus macaques (Macaca mulatta, Mamu) are valuable as a preclinical model species in transplantation research as well as to evaluate the safety and efficacy of vaccine candidates. In both lines of research, the availability of nonhuman primate MHC-reactive mAbs may enable in vitro monitoring and detection of presence of particular Mamu molecules. In this study, we screened a collection of thoroughly characterized HLA class I-specific human mAbs for cross-reactivity with rhesus macaque MHC class I allotypes. Two mAbs, OK4F9 and OK4F10, recognize an epitope that is defined by isoleucine (I) at amino acid position 142 that is present on the Indian rhesus macaque Mamu-B*008:01 allotype, which is an allotype known to be associated with elite control of SIV replication. The reactive pattern of a third mAb, MUS4H4, is more complex and includes an epitope shared on Mamu-A2*05:01 and -B*001:01-encoded Ags. This is the first description, to our knowledge, of human HLA-reactive mAbs that can recognize Mamu allotypes, and these can be useful tools for in vitro monitoring the presence of the relevant allelic products. Moreover, OK4F9 and OK4F10 can be powerful mAbs for application in SIV-related research.


Subject(s)
Acquired Immunodeficiency Syndrome/immunology , HIV-1/physiology , HLA Antigens/immunology , Histocompatibility Antigens Class I/metabolism , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Immunodeficiency Virus/physiology , Acquired Immunodeficiency Syndrome/genetics , Alleles , Animals , Antibodies, Monoclonal/metabolism , Cross Reactions , Genetic Predisposition to Disease , HLA Antigens/genetics , Histocompatibility Antigens Class I/genetics , Humans , Immunoglobulin Allotypes , K562 Cells , Macaca mulatta , Polymorphism, Genetic , Simian Acquired Immunodeficiency Syndrome/genetics , Virus Replication
5.
Platelets ; 34(1): 2129604, 2023 Dec.
Article in English | MEDLINE | ID: mdl-36185007

ABSTRACT

Immune-mediated platelet refractoriness (PR) remains a significant problem in the setting of platelet transfusion and is predominantly caused by the presence of alloantibodies directed against class I human leukocyte antigens (HLA). Opsonization of donor platelets with these alloantibodies can result in rapid clearance after transfusion via multiple mechanisms, including antibody dependent cellular phagocytosis (ADCP). Interestingly, not all alloimmunized patients develop PR to unmatched platelet transfusions, suggesting variation in HLA-specific IgG responses between patients. Previously, we observed that the glycosylation profile of anti-HLA antibodies was highly variable between PR patients, especially with respect to Fc galactosylation, sialylation and fucosylation. In the current study, we investigated the effect of different Fc glycosylation patterns, with known effects on complement deposition and FcγR binding, on phagocytosis of opsonized platelets by monocyte-derived human macrophages. We found that the phagocytosis of antibody- and complement-opsonized platelets, by monocyte derived M1 macrophages, was unaffected by these qualitative IgG-glycan differences.


Subject(s)
Isoantibodies , Platelet Transfusion , Humans , Blood Platelets/metabolism , Phagocytosis , Macrophages , Immunoglobulin G , Complement System Proteins/metabolism , HLA Antigens
6.
Eur J Immunol ; 51(3): 734-737, 2021 03.
Article in English | MEDLINE | ID: mdl-33275281

ABSTRACT

A single model system for integrative studies on multiple facets of antigen presentation is lacking. PAKC is a novel panel of ten cell lines knocked out for individual components of the HLA class I antigen presentation pathway. PAKC will accelerate HLA-I research in the fields of oncology, infectiology, and autoimmunity.


Subject(s)
Antigen Presentation/immunology , Histocompatibility Antigens Class I/immunology , Autoimmunity/immunology , Humans , Neoplasms/immunology , Signal Transduction/immunology
7.
Haematologica ; 107(10): 2432-2444, 2022 10 01.
Article in English | MEDLINE | ID: mdl-35354253

ABSTRACT

Approximately 20% of patients receiving multiple platelet transfusions develop platelet alloantibodies, which can be directed against human leukocyte antigens (HLA) and, to a lesser extent, against human platelet antigens (HPA). These antibodies can lead to the rapid clearance of donor platelets, presumably through IgG-Fc receptor (FcγR)-mediated phagocytosis or via complement activation, resulting in platelet refractoriness. Strikingly, not all patients with anti-HLA or -HPA antibodies develop platelet refractoriness upon unmatched platelet transfusions. Previously, we found that IgG Fc glycosylation of anti-HLA antibodies was highly variable between patients with platelet refractoriness, especially with respect to galactosylation and sialylation of the Fc-bound sugar moiety. Here, we produced recombinant glycoengineered anti-HLA and anti- HPA-1a monoclonal antibodies with varying Fc galactosylation and sialylation levels and studied their ability to activate the classical complement pathway. We observed that anti-HLA monoclonal antibodies with different specificities, binding simultaneously to the same HLA-molecules, or anti-HLA in combination with anti-HPA-1a monoclonal antibodies interacted synergistically with C1q, the first component of the classical pathway. Elevated Fc galactosylation and, to a lesser extent, sialylation significantly increased the complement-activating properties of anti-HLA and anti-HPA-1a monoclonal antibodies. We propose that both the breadth of the polyclonal immune response, with recognition of different HLA epitopes and in some cases HPA antigens, and the type of Fc glycosylation can provide an optimal stoichiometry for C1q binding and subsequent complement activation. These factors can shift the effect of a platelet alloimmune response to a clinically relevant response, leading to complement-mediated clearance of donor platelets, as observed in platelet refractoriness.


Subject(s)
Antigens, Human Platelet , Thrombocytopenia , Antibodies, Monoclonal/pharmacology , Antigens, Human Platelet/metabolism , Blood Platelets/metabolism , Complement C1q , Complement Pathway, Classical , Complement System Proteins/metabolism , Epitopes , HLA Antigens , Humans , Immunoglobulin G/metabolism , Isoantibodies , Receptors, IgG/metabolism , Sugars/metabolism , Thrombocytopenia/metabolism
8.
J Immunol ; 202(2): 451-459, 2019 01 15.
Article in English | MEDLINE | ID: mdl-30559321

ABSTRACT

The intracellular pathway of cross-presentation, which allows MHC class I-restricted presentation of peptides derived from exogenous Ags, remains poorly defined and may vary with the nature of the exogenous Ag and the type of APC. It can be cytosolic, characterized by proteasome and TAP dependency, or vacuolar, usually believed to be proteasome and TAP independent. Cross-presentation is particularly effective with long synthetic peptides, and we previously reported that the HLA-A2-restricted cross-presentation of a long peptide derived from melanoma Ag gp100 by human monocyte-derived immature dendritic cells occurred in a vacuolar pathway, making use of newly synthesized HLA-A2 molecules that follow a nonclassical secretion route. In this article, we show that the HLA-A1-restricted cross-presentation of a long peptide derived from tumor Ag MAGE-A3 by human monocyte-derived immature dendritic cells also follows a vacuolar pathway. However, as opposed to the HLA-A2-restricted peptide, cross-presentation of the HLA-A1-restricted peptide is TAP dependent. We show that this paradoxical TAP-dependency is indirect and reflects the need for TAP to load HLA-A1 molecules with peptides in the endoplasmic reticulum, to allow them to escape the endoplasmic reticulum and reach the vacuole, where peptide exchange with the cross-presented peptide likely occurs. Our results confirm and extend the involvement of the vacuolar pathway in the cross-presentation of long peptides, and indicate that TAP-dependency can no longer be used as a key criterion to distinguish the cytosolic from the vacuolar pathway of cross-presentation. They also stress the existence of an alternative secretory route for MHC class I, which will be worthy of further studies.


Subject(s)
ATP-Binding Cassette Transporters/metabolism , Antigens, Neoplasm/metabolism , Dendritic Cells/immunology , Endoplasmic Reticulum/metabolism , HLA-A1 Antigen/metabolism , Neoplasm Proteins/metabolism , T-Lymphocytes, Cytotoxic/immunology , Vacuoles/metabolism , Antigen Presentation , Cell Line , Cross-Priming , Cytosol/metabolism , HLA-A2 Antigen/metabolism , Humans , Peptides/metabolism , gp100 Melanoma Antigen/metabolism
9.
Am J Transplant ; 20(10): 2686-2702, 2020 10.
Article in English | MEDLINE | ID: mdl-32320528

ABSTRACT

HLA donor-specific antibodies (DSAs) binding to vascular endothelial cells of the allograft trigger inflammation, vessel injury, and antibody-mediated rejection (AMR). Accumulation of intragraft-recipient macrophages is a histological characteristic of AMR, which portends worse outcome. HLA class I (HLA I) DSAs enhance monocyte recruitment by activating endothelial cells and engaging FcγRs, but the DSA-activated donor endothelial influence on macrophage differentiation is unknown. In this study, we explored the consequence of DSA-activated endothelium on infiltrating monocyte differentiation. Here we show that cardiac allografts from murine recipients treated with MHC I DSA upregulated genes related to monocyte transmigration and Fc receptor stimulation. Human monocytes co-cultured with HLA I IgG-stimulated primary human endothelium promoted monocyte differentiation into CD68+ CD206+ CD163+ macrophages (M(HLA I IgG)), whereas HLA I F(ab')2 stimulated endothelium solely induced higher CD206 (M(HLA I F(ab')2 )). Both macrophage subtypes exhibited significant changes in discrete cytokines/chemokines and unique gene expression profiles. Cross-comparison of gene transcripts between murine DSA-treated cardiac allografts and human co-cultured macrophages identified overlapping genes. These findings uncover the role of HLA I DSA-activated endothelium in monocyte differentiation, and point to a novel, remodeling phenotype of infiltrating macrophages that may contribute to vascular injury.


Subject(s)
Endothelial Cells , Graft Rejection , Allografts , Animals , Graft Rejection/etiology , HLA Antigens , Humans , Inflammation/etiology , Isoantibodies , Macrophages , Mice , Phenotype , Tissue Donors
10.
Blood ; 131(1): 144-152, 2018 01 04.
Article in English | MEDLINE | ID: mdl-29092829

ABSTRACT

Patients refractory to platelet transfusions because of alloimmunization require HLA-matched platelets, which is only possible if a large HLA-typed donor pool is available. However, even then, patients with broad immunization or rare haplotypes may not have suitable donors. In these patients, transfusions with platelets showing low HLA class I expression may be an alternative to fully HLA-matched transfusions. In this study, we quantified the proportion of donors with consistently low HLA-B8, -B12, and -B35 expression on platelets using human monoclonal antibodies specific for these antigens. Furthermore, as model for in vivo clearance, antibody-mediated internalization of these platelets by macrophages was investigated. The expression of HLA-B8, -B12, or -B35 on platelets was extremely variable between individuals (coefficients of variation, 41.4% to 73.6%). For HLA-B8, but not for HLA-B12 or -B35, this variation was in part explained by zygosity. The variation was most pronounced in, but not exclusive to, platelets. Expression within one donor was consistent over time. Remarkably, 32% of 113 HLA-B8, 34% of 98 HLA-B12, and 9% of 66 HLA-B35 donors showed platelet antigen expression that was not or only minimally above background. Antibody-mediated internalization of platelets by macrophages correlated with antibody opsonization and antigen expression and was absent in platelets with low or minimal HLA expression. In conclusion, our findings indicate that a substantial proportion of donors have platelets with consistently low expression of specific HLA class I antigens. These platelets may be used to treat refractory patients with antibodies directed against these particular antigens, despite HLA mismatches.


Subject(s)
Blood Platelets/immunology , HLA-B Antigens/metabolism , HLA-B35 Antigen/metabolism , HLA-B8 Antigen/metabolism , Isoantibodies/immunology , Macrophages/metabolism , Tissue Donors , Blood Platelets/metabolism , HLA-B Antigens/immunology , HLA-B35 Antigen/immunology , HLA-B8 Antigen/immunology , Histocompatibility Testing , Humans , Macrophages/immunology , Patient Selection , Platelet Transfusion/standards
11.
Am J Transplant ; 19(5): 1371-1379, 2019 05.
Article in English | MEDLINE | ID: mdl-30548563

ABSTRACT

Tissue resident lymphocytes are present within many organs, and are presumably transferred at transplantation, but their impact on host immunity is unclear. Here, we examine whether transferred donor natural regulatory CD4 T cells (nT-regs) inhibit host alloimmunity and prolong allograft survival. Transfer of donor-strain lymphocytes was first assessed by identifying circulating donor-derived CD4 T cells in 21 consecutive human lung transplant recipients, with 3 patterns of chimerism apparent: transient, intermediate, and persistent (detectable for up to 6 weeks, 6 months, and beyond 1 year, respectively). The potential for transfer of donor nT-regs was then confirmed by analysis of leukocyte filters recovered from ex vivo normothermic perfusion circuits of human kidneys retrieved for transplantation. Finally, in a murine model of cardiac allograft vasculopathy, depletion of donor CD4 nT-regs before organ recovery resulted in markedly accelerated heart allograft rejection and augmented host effector antibody responses. Conversely, adoptive transfer or purified donor-strain nT-regs inhibited host humoral immunity and prolonged allograft survival, and more effectively so than following administration of recipient nT-regs. In summary, following transplantation, passenger donor-strain nT-regs can inhibit host adaptive immune responses and prolong allograft survival. Isolated donor-derived nT-regs may hold potential as a cellular therapy to improve transplant outcomes.


Subject(s)
Graft Rejection/immunology , Graft Survival/immunology , Kidney Transplantation , Lung Transplantation , T-Lymphocytes, Regulatory/immunology , Adoptive Transfer , Allografts , Animals , Cell Lineage , Heart Transplantation , Humans , Immune System , Immunity, Humoral , Isoantibodies/immunology , Mice , Organ Preservation , Perfusion , Tissue Donors , Transplantation, Homologous , Treatment Outcome
12.
J Cell Sci ; 130(17): 2883-2892, 2017 Sep 01.
Article in English | MEDLINE | ID: mdl-28743740

ABSTRACT

Misfolded endoplasmic reticulum (ER) proteins are dislocated towards the cytosol and degraded by the ubiquitin-proteasome system in a process called ER-associated protein degradation (ERAD). During infection with human cytomegalovirus (HCMV), the viral US2 protein targets HLA class I molecules (HLA-I) for degradation via ERAD to avoid elimination by the immune system. US2-mediated degradation of HLA-I serves as a paradigm of ERAD and has facilitated the identification of TRC8 (also known as RNF139) as an E3 ubiquitin ligase. No specific E2 enzymes had previously been described for cooperation with TRC8. In this study, we used a lentiviral CRISPR/Cas9 library targeting all known human E2 enzymes to assess their involvement in US2-mediated HLA-I downregulation. We identified multiple E2 enzymes involved in this process, of which UBE2G2 was crucial for the degradation of various immunoreceptors. UBE2J2, on the other hand, counteracted US2-induced ERAD by downregulating TRC8 expression. These findings indicate the complexity of cellular quality control mechanisms, which are elegantly exploited by HCMV to elude the immune system.


Subject(s)
Cytomegalovirus/metabolism , Down-Regulation , Receptors, Immunologic/metabolism , Ubiquitin-Conjugating Enzymes/metabolism , Viral Envelope Proteins/metabolism , CRISPR-Cas Systems/genetics , Genetic Testing , Histocompatibility Antigens Class I/metabolism , Humans , Models, Biological , Proteolysis , Receptors, Cell Surface/metabolism , U937 Cells , Up-Regulation
13.
Haematologica ; 104(2): 403-416, 2019 02.
Article in English | MEDLINE | ID: mdl-30262558

ABSTRACT

High titers of HLA antibodies are associated with platelet refractoriness, causing poor platelet increments after transfusions in a subset of patients with HLA antibodies. Currently, we do not know the biological mechanisms that explain the variability in clinical responses in HLA alloimmunized patients receiving platelet transfusions. Previously we showed that a subset of anti-HLA IgG-antibodies induces FcγRIIa-dependent platelet activation and enhanced phagocytosis. Here, we investigated whether anti-HLA IgG can induce complement activation on platelets. We found that a subset of anti-HLA IgG induced complement activation via the classical pathway, causing C4b and C3b deposition and formation of the membrane-attack complex. This resulted in permeabilization of platelet membranes and increased calcium influx. Complement activation also caused enhanced α-granule release, as measured by CD62P surface exposure. Blocking studies revealed that platelet activation was caused by FcγRIIa-dependent signaling as well as HLA antibody induced complement activation. Synergistic complement activation employing combinations of monoclonal IgGs suggested that assembly of oligomeric IgG complexes strongly promoted complement activation through binding of IgGs to different antigenic determinants on HLA. In agreement with this, we observed that preventing anti-HLA-IgG hexamer formation using an IgG-Fc:Fc blocking peptide, completely inhibited C3b and C4b deposition. Our results show that HLA antibodies can induce complement activation on platelets including membrane attack complex formation, pore formation and calcium influx. We propose that these events can contribute to fast platelet clearance in vivo in patients refractory to platelet transfusions with HLA alloantibodies, who may benefit from functional-platelet matching and treatment with complement inhibitors.


Subject(s)
Blood Platelets/immunology , Complement Pathway, Classical/immunology , Complement System Proteins/immunology , HLA Antigens/immunology , Isoantibodies/immunology , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/pharmacology , Blood Platelets/metabolism , Calcium/metabolism , Complement Pathway, Classical/drug effects , Complement System Proteins/metabolism , Dose-Response Relationship, Drug , Flow Cytometry , Humans , Immunoglobulin G/immunology , Immunoglobulin G/pharmacology , Immunoglobulins, Intravenous/pharmacology , Isoantibodies/pharmacology , Models, Biological , Platelet Activation/drug effects , Protein Binding , Receptors, IgG/metabolism
14.
Transpl Int ; 32(1): 16-24, 2019 01.
Article in English | MEDLINE | ID: mdl-30341790

ABSTRACT

Recent data suggest that HLA epitope matching is beneficial for the prevention of de novo donor specific antibody (DSA) formation after transplantation. In this review, different approaches to predict the immunogenicity of an HLA mismatch will be discussed. The parameters used in these models are often called epitopes but the actual antibody epitope is far more complex. Exact knowledge of the antibody epitope is crucial if epitope matching is also used as a tool to select compatible donors for (highly) sensitized patients. Evidence is provided that it is not always possible to give an exact definition of an antibody epitope. We conclude that HLA "epitope" matching is superior over HLA antigen matching with respect to the prevention of de novo DSA formation and will enhance the prediction of acceptable HLA mismatches for sensitized patients. However, epitope matching at our current level of knowledge will not solve all histocompatibility problems as unexpected antibody reactivity still may occur.


Subject(s)
Epitopes/chemistry , Histocompatibility Testing/methods , Isoantibodies/immunology , Alleles , Antibody Formation , Europe , Graft Rejection/immunology , HLA Antigens/immunology , Histocompatibility Antigens/immunology , Humans , Immunoglobulin G/immunology , Kidney Transplantation , Reoperation , Tissue Donors , Tissue and Organ Procurement , Waiting Lists
15.
Haematologica ; 103(10): 1741-1752, 2018 10.
Article in English | MEDLINE | ID: mdl-29858387

ABSTRACT

HLA antibodies are associated with refractoriness to platelet transfusion, leading to rapid platelet clearance, sometimes coinciding with clinical side effects such as fever and chills. The presence of HLA antibodies is not always manifested by clinical symptoms. It is currently unclear why refractoriness to platelet transfusion is only observed in a subset of patients. Here, we utilized the availability of a unique panel of human monoclonal antibodies to study whether these were capable of activating platelets. Three out of eight human HLA-specific monoclonal antibodies induced activation of HLA-matched platelets from healthy donors as evidenced by enhanced α-granule release, aggregation, and αIIbb3 activation. The propensity of HLA monoclonal antibodies to activate platelets was independent of the HLA subtype to which they were directed, but was dependent on the recognized epitope. Activation was fully inhibited either by blocking FcγRIIa, or by blocking FcγRIIa-dependent signaling with Syk inhibitor IV. Furthermore, activation required the presence of the IgG-Fc part, as F(ab')2 fragments of HLA monoclonal antibodies were unable to induce platelet activation. Mixing experiments revealed that activation of platelets occurred in an intra-platelet dependent manner. Accordingly, a proportion of sera from refractory patients with HLA antibodies induced FcγRIIa-dependent platelet activation. Our data show that a subset of HLA antibodies is capable of crosslinking HLA and FcγRIIa thereby promoting platelet activation and enhancing these cells' phagocytosis by macrophages. Based on these findings we suggest that FcγRIIa-dependent platelet activation may contribute to the decreased platelet survival in platelet-transfusion-dependent patients with HLA antibodies.


Subject(s)
Antibodies, Monoclonal/pharmacology , Blood Platelets/metabolism , HLA Antigens/metabolism , Immunoglobulin G/pharmacology , Platelet Activation/drug effects , Receptors, IgG/metabolism , Humans , Immunoglobulin Fab Fragments/pharmacology , Immunoglobulin Fc Fragments/pharmacology
16.
J Immunol ; 196(2): 750-8, 2016 Jan 15.
Article in English | MEDLINE | ID: mdl-26685209

ABSTRACT

MHC haplotypes of humans and the African great ape species have one copy of the MHC-A, -B, and -C genes. In contrast, MHC haplotypes of orangutans, the Asian great ape species, exhibit variation in the number of gene copies. An in-depth analysis of the MHC class I gene repertoire in the two orangutan species, Pongo abelii and Pongo pygmaeus, is presented in this article. This analysis involved Sanger and next-generation sequencing methodologies, revealing diverse and complicated transcription profiles for orangutan MHC-A, -B, and -C. Thirty-five previously unreported MHC class I alleles are described. The data demonstrate that each orangutan MHC haplotype has one copy of the MHC-A gene, and that the MHC-B region has been subject to duplication, giving rise to at least three MHC-B genes. The MHC-B*03 and -B*08 lineages of alleles each account for a separate MHC-B gene. All MHC-B*08 allotypes have the C1-epitope motif recognized by killer cell Ig-like receptor. At least one other MHC-B gene is present, pointing to MHC-B alleles that are not B*03 or B*08. The MHC-C gene is present only on some haplotypes, and each MHC-C allotype has the C1-epitope. The transcription profiles demonstrate that MHC-A alleles are highly transcribed, whereas MHC-C alleles, when present, are transcribed at very low levels. The MHC-B alleles are transcribed to a variable extent and over a wide range. For those orangutan MHC class I allotypes that are detected by human monoclonal anti-HLA class I Abs, the level of cell-surface expression of proteins correlates with the level of transcription of the allele.


Subject(s)
Genes, MHC Class I , Pongo abelii/genetics , Pongo pygmaeus/genetics , Transcriptome , Amino Acid Sequence , Animals , Evolution, Molecular , Haplotypes , High-Throughput Nucleotide Sequencing , Humans , Phylogeny , Reverse Transcriptase Polymerase Chain Reaction
17.
Biol Reprod ; 96(4): 831-842, 2017 Apr 01.
Article in English | MEDLINE | ID: mdl-28340094

ABSTRACT

During pregnancy, fetal extravillous trophoblasts (EVT) play a key role in the regulation of maternal T cell and NK cell responses. EVT display a unique combination of human leukocyte antigens (HLA); EVT do not express HLA-A and HLA-B, but do express HLA-C, HLA-E, and HLA-G. The mechanisms establishing this unique HLA expression pattern have not been fully elucidated. The major histocompatibility complex (MHC) class I and class II transcriptional activators NLRC5 and CIITA are expressed neither by EVT nor by the EVT model cell line JEG3, which has an MHC expression pattern identical to that of EVT. Therefore, other MHC regulators must be present to control HLA-C, HLA-E, and HLA-G expression in these cells. CIITA and NLRC5 are both members of the nucleotide-binding domain, leucine-rich repeat (NLR) family of proteins. Another member of this family, NLRP2, is highly expressed by EVT and JEG3, but not in maternal decidual stromal cells. In this study, transcription activator-like effector nuclease technology was used to delete NLRP2 in JEG3. Furthermore, lentiviral delivery of shRNA was used to knockdown NLRP2 in JEG3 and primary EVT. Upon NLRP2 deletion, Tumor Necrosis Factor-α (TNFα)-induced phosphorylation of NF-KB p65 increased in JEG3 and EVT, and more surprisingly a significant increase in constitutive HLA-C expression was observed in JEG3. These data suggest a broader role for NLR family members in the regulation of MHC expression during inflammation, thus forming a bridge between innate and adaptive immune responses. As suppressor of proinflammatory responses, NLRP2 may contribute to preventing unwanted antifetal responses.


Subject(s)
Adaptor Proteins, Signal Transducing/metabolism , Gene Expression Regulation, Developmental/physiology , HLA-C Antigens/metabolism , NF-kappa B/metabolism , Trophoblasts/metabolism , Adaptor Proteins, Signal Transducing/genetics , Apoptosis Regulatory Proteins , Cell Line , Cytokines/genetics , Cytokines/metabolism , Gene Deletion , Genes, MHC Class I/genetics , HLA-C Antigens/genetics , Humans , NF-kappa B/genetics , Phosphorylation , RNA, Messenger/genetics , RNA, Messenger/metabolism , Signal Transduction
18.
Eur J Immunol ; 45(2): 492-500, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25359276

ABSTRACT

Natural killer cells are controlled by peptide selective inhibitory receptors for MHC class I, including the killer cell immunoglobulin-like receptors (KIRs). Despite having similar ligands, KIR2DL2 and KIR2DL3 confer different levels of protection to infectious disease. To investigate how changes in peptide repertoire may differentially affect NK cell reactivity, NK cells from KIR2DL2 and KIR2DL3 homozygous donors were tested for activity against different combinations of strong inhibitory (VAPWNSFAL), weak inhibitory (VAPWNSRAL), and antagonist peptide (VAPWNSDAL). KIR2DL3-positive NK cells were more sensitive to changes in the peptide content of MHC class I than KIR2DL2-positive NK cells. These differences were observed for the weakly inhibitory peptide VAPWNSRAL in single peptide and double peptide experiments (p < 0.01 and p < 0.03, respectively). More significant differences were observed in experiments using all three peptides (p < 0.0001). Mathematical modeling of the experimental data demonstrated that VAPWNSRAL was dominant over VAPWNSFAL in distinguishing KIR2DL3- from KIR2DL2-positive donors. Donors with different KIR genotypes have different responses to changes in the peptide bound by MHC class I. Differences in the response to the peptide content of MHC class I may be one mechanism underlying the protective effects of different KIR genes against infectious disease.


Subject(s)
Killer Cells, Natural/immunology , Models, Statistical , Peptides/immunology , Receptors, KIR2DL2/genetics , Receptors, KIR2DL3/genetics , Amino Acid Sequence , Cell Degranulation , Gene Expression Regulation , Genotype , HLA-C Antigens/genetics , HLA-C Antigens/immunology , Homozygote , Humans , Killer Cells, Natural/cytology , Killer Cells, Natural/metabolism , Ligands , Molecular Sequence Data , Peptides/chemistry , Primary Cell Culture , Protein Binding , Receptors, KIR2DL2/immunology , Receptors, KIR2DL3/immunology , Structure-Activity Relationship
19.
Proc Natl Acad Sci U S A ; 110(42): 16981-6, 2013 Oct 15.
Article in English | MEDLINE | ID: mdl-24082146

ABSTRACT

Peptide selectivity is a feature of inhibitory receptors for MHC class I expressed by natural killer (NK) cells. CD94-NKG2A operates in tandem with the polymorphic killer cell Ig-like receptors (KIR) and Ly49 systems to inhibit NK cells. However, the benefits of having two distinct inhibitory receptor-ligand systems are not clear. We show that noninhibitory peptides presented by HLA-E can augment the inhibition of NKG2A(+) NK cells mediated by MHC class I signal peptides through the engagement of CD94 without a signaling partner. Thus, CD94 is a peptide-selective NK cell receptor, and NK cells can be regulated by nonsignaling interactions. We also show that KIR(+) and NKG2A(+) NK cells respond with differing stoichiometries to MHC class I down-regulation. MHC-I-bound peptide functions as a molecular rheostat controlling NK cell function. Selected peptides which in isolation do not inhibit NK cells can have different effects on KIR and NKG2A receptors. Thus, these two inhibitory systems may complement each other by having distinct responses to bound peptide and surface levels of MHC class I.


Subject(s)
Histocompatibility Antigens Class I/immunology , Killer Cells, Natural/immunology , Lymphocyte Activation/physiology , NK Cell Lectin-Like Receptor Subfamily D/immunology , Histocompatibility Antigens Class I/metabolism , Humans , Jurkat Cells , Killer Cells, Natural/metabolism , NK Cell Lectin-Like Receptor Subfamily C/immunology , NK Cell Lectin-Like Receptor Subfamily C/metabolism , NK Cell Lectin-Like Receptor Subfamily D/metabolism , Peptides/immunology , Peptides/metabolism , Receptors, KIR/immunology , Receptors, KIR/metabolism , HLA-E Antigens
20.
Biol Blood Marrow Transplant ; 21(2): 233-41, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25445022

ABSTRACT

A major challenge in unrelated hematopoietic stem cell transplantation (HSCT) is the prediction of permissive HLA mismatches, ie, those associated with lower clinical risks compared to their nonpermissive counterparts. For HLA-DPB1, a clinically prognostic model has been shown to be matching for T cell epitope (TCE) groups assigned by cross reactivity of T cells alloreactive to HLA-DPB1∗09:01; however, the molecular basis of this observation is not fully understood. Here, we have mutated amino acids (aa) in 10 positions of HLA-DPB1∗09:01 to other naturally occurring variants, expressed them by lentiviral vectors in B cell lines, and quantitatively measured allorecognition by 17 CD4(+) T cell effectors from 6 unrelated individuals. A significant impact on the median alloresponse was observed for peptide contact positions 9, 11, 35, 55, 69, 76, and 84, but not for positions 8, 56, and 57 pointing away from the groove. A score for the "functional distance" (FD) from HLA-DPB1∗09:01 was defined as the sum of the median impact of polymorphic aa in a given HLA-DPB1 allele on T cell alloreactivity. Established TCE group assignment of 23 alleles correlated with FD scores of ≤0.5, 0.6 to 1.9 and ≥2 for TCE groups 1, 2, and 3, respectively. Based on this, prediction of TCE group assignment will be possible for any given HLA-DPB1 allele, including currently 367 alleles encoding distinct proteins for which T cell cross reactivity patterns are unknown. Experimental confirmation of the in silico TCE group classification was successfully performed for 7 of 7 of these alleles. Our findings have practical implications for the applicability of TCE group matching in unrelated HSCT and provide new insights into the molecular mechanisms underlying this model. The innovative concept of FD opens new potential avenues for risk prediction in unrelated HSCT.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Epitopes, T-Lymphocyte/immunology , HLA-DP beta-Chains/immunology , Hematopoietic Stem Cell Transplantation , Mutation , Protein Isoforms/immunology , Alleles , Amino Acids/chemistry , Amino Acids/immunology , B-Lymphocytes/cytology , B-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/cytology , Cell Line , Clone Cells , Epitopes, T-Lymphocyte/chemistry , Epitopes, T-Lymphocyte/classification , Gene Expression , HLA-DP beta-Chains/chemistry , HLA-DP beta-Chains/classification , HLA-DP beta-Chains/genetics , Histocompatibility Testing , Humans , Protein Isoforms/chemistry , Protein Isoforms/classification , Protein Isoforms/genetics , Transplantation, Homologous , Unrelated Donors
SELECTION OF CITATIONS
SEARCH DETAIL